Karessa announces that the plan for the two projects K-01 and K-03 remains unchanged

Karessa Pharma Holding AB announces today that the plan presented in December about the development of K-01 and K-03 remains until further notice.Karessa pledged in December that a revision of the overall development and registration plan should be available in Q1 2017. Newly-appointed CEO Michael Brobjer finds that the plan presented for the two projects remains unchanged until further notice. This means that a Proof of Concept clinical study shall be perform for the projects to obtain initial clinical data before initiating a pivotal clinical programme. Karessa Pharma's project K-01 is